Open AccessThe therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers
Author(s) -
Danny Vesprini,
Steven A. Narod,
John Trachtenberg,
Juanita Crook,
Farid Jalali,
John Preiner,
Srikala S. Sridhar,
Robert G. Bristow
Publication year - 2013
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.477
H-Index - 38
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.619
Subject(s) - medicine , cisplatin , radiation therapy , toxicity , oncology , prostate cancer , therapeutic index , parp inhibitor , cancer research , chemotherapy , poly adp ribose polymerase , pharmacology , cancer , drug , biology , biochemistry , polymerase , gene
Prostate cancers in patients with a mutation in BRCA2 have earlierdisease onset and an aggressive course, often necessitatingthe use of systemic therapy. However, these tumours are DNArepair-defective and could respond favourably to Parp inhibitors orDNA-damaging agents, depending on the therapeutic ratio (ratio oftumour response to normal tissue toxicity). We describe 3 patientstreated with precision radiotherapy or cisplatin who respondedfavourably to both agents, yet did not suffer undue toxicity. Wereview the concept of treating such patients with agents that areselectively toxic to repair-deficient tumours.